EnChannel Medical raised $82.2M in Series B financing, co-led by Dragonball Capital and Lilly Asia Ventures, to accelerate product development and advance clinical trials.

May 01, 2025•8 months ago

Amount Raised

$82.2 Million

Round Type

series b

GuangzhouMedicalBiotechnologyHealth Care

Investors

Lapam CapitalLilly Asia VenturesDragonball Capital

Description

EnChannel Medical, based in Guangzhou, China, closed a Series B financing round, raising $82.2M. The funding will support product development and clinical registration trials globally. The round was co-led by Dragonball Capital and Lilly Asia Ventures. Founded in 2020, EnChannel focuses on innovations in cardiac electrophysiology.

Company Information

Company

EnChannel Medical

Location

Guangzhou, Guangdong, China

About

EnChannel Medical is an innovator in cardiac electrophysiology, developing a holistic platform for personalized treatment of atrial fibrillation. Founded in 2020, the company is led by seasoned electrophysiology experts and aims to unify several advanced technologies in cardiac treatment. The company has secured significant funding to enhance product development and clinical trials worldwide. EnChannel is headquartered in Guangzhou, China, with an R&D subsidiary in Irvine, California.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends